Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Zions Bancorporation N.A.

Zions Bancorporation N.A. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVOFree Report) by 57.0% in the third quarter, HoldingsChannel reports. The firm owned 18,535 shares of the company’s stock after purchasing an additional 6,726 shares during the quarter. Zions Bancorporation N.A.’s holdings in Novo Nordisk A/S were worth $2,207,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. 1620 Investment Advisors Inc. bought a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC lifted its position in shares of Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $25,000. Orion Capital Management LLC acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $26,000. Finally, Halpern Financial Inc. lifted its position in shares of Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after acquiring an additional 113 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVO. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Buy” and an average price target of $144.50.

View Our Latest Analysis on Novo Nordisk A/S

Novo Nordisk A/S Trading Down 1.5 %

Shares of NYSE:NVO opened at $105.35 on Friday. The stock has a market capitalization of $472.76 billion, a PE ratio of 34.09, a P/E/G ratio of 1.31 and a beta of 0.42. Novo Nordisk A/S has a 1 year low of $94.73 and a 1 year high of $148.15. The firm has a fifty day moving average price of $119.68 and a 200 day moving average price of $129.92. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

(Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Read More

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOFree Report).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.